Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 568 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total transaction of $14,870.24. Following the transaction, the chief operating officer now owns 236,286 shares of the company's stock, valued at $6,185,967.48. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Jonathan Young also recently made the following trade(s):
- On Thursday, August 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.75, for a total transaction of $133,750.00.
- On Monday, July 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $23.40, for a total transaction of $117,000.00.
Akero Therapeutics Stock Up 6.4 %
Shares of NASDAQ:AKRO opened at $27.34 on Friday. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $25.99 and a 200 day simple moving average of $23.99. The firm has a market cap of $1.90 billion, a PE ratio of -8.54 and a beta of -0.26. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $53.77.
Is Starlink Set For The Largest IPO In History?
From Paradigm Press | Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant.
Then, he did it again with Tesla… which is up more than 19,500% since 2010.
For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.09. On average, equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.
Institutional Trading of Akero Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in Akero Therapeutics by 247.7% during the fourth quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company's stock valued at $67,294,000 after purchasing an additional 2,053,028 shares during the last quarter. Vanguard Group Inc. increased its stake in Akero Therapeutics by 19.0% during the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company's stock valued at $92,702,000 after purchasing an additional 584,875 shares during the last quarter. Capstone Investment Advisors LLC bought a new stake in Akero Therapeutics during the first quarter valued at $2,205,000. Seven Eight Capital LP bought a new stake in Akero Therapeutics during the fourth quarter valued at $1,459,000. Finally, UBS Group AG increased its stake in Akero Therapeutics by 356.1% during the fourth quarter. UBS Group AG now owns 266,386 shares of the company's stock valued at $6,220,000 after purchasing an additional 207,983 shares during the last quarter.
Analysts Set New Price Targets
AKRO has been the topic of several research analyst reports. Wolfe Research initiated coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They issued an "outperform" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $41.13.
Read Our Latest Research Report on AKRO
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
